Aim: To investigate the protective effects of ginsenoside Rb 3 , a triterpenoid saponin isolated from the leaves of Panax notoginseng, on ischemic and reperfusion injury model of PC12 cells and elucidate the related mechanisms. Methods: PC12 cells exposed to oxygen and glucose deprivation (OGD) and restoration (OGD-Rep) were used as an in vitro model of ischemia and reperfusion. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and lactate dehydrogenase (LDH) leakage were used to evaluate the protective effects of ginsenoside Rb 3 . Cellular apoptosis and mitochondrial membrane potential (MMP) were analyzed using flow cytometry. Intracellular calcium ion concentration ([Ca 2+ ] i ) was detected using fluorophotometer system. Caspase-3, -8, and -9 activities were measured using assay kits with an ELISA reader. Western blotting assay was used to evaluate the release of cytochrome c and expression of caspase-3, Bcl-2 and Bax proteins. Results: It was shown that ginsenoside Rb 3 (0.1-10 μmol/L) significantly increased cell viability and inhibited LDH release in a dosedependent manner on the ischemic model. In addition, ginsenoside Rb 3 also significantly inhibited ischemic injury-induced apoptosis, [Ca 2+ ] i elevation, and decrease of MMP. Meanwhile, pretreatment with ginsenoside Rb 3 significantly induced an increase of Bcl-2 protein expression and a decrease of cytosolic cytochrome c, cleaved-caspase 3 and Bax protein expression, the caspase-3, -8, and -9 activity were also inhibited.
Introduction
Nowadays, focal cerebral ischemia is a leading cause of death and disability in the aged population all around the world. Focal cerebral ischemia is a disease characterized by obstructing of blood flow to the brain, resulting in deficient supply of glucose, oxygen, serum, and nutrient that are indispensable for the energy generation [1] . Neuronal injury induced by cerebral ischemia/reperfusion, is a very complex process with multiple mechanism, such as excitotoxicity, oxidative stress, apoptosis, and variations in gene expression or the activation of kinase [2, 3] . Mitochondria are vital cell organs in the process of transmitting apoptosis signs through releasing apoptotic factors into the cytosol [4, 5] , ischemia/reperfusion-induced mitochondrial dysfunction plays a central role in cell death through controlling cellular energy metabolism. Mitochondrium was recently believed to be a good therapeutic target for the cerebral ischemia [6] . PC12 cell line is initially derived from a rat adrenal medullary pheochromocytoma, which expressed electrical excitability and calcium channels, possessing the phenotypic and genotypic properties of sympathetic neurons when differentiated by NGF [7, 8] . Therefore, NGF-differentiated PC12 cell line was commonly and widely used as a replacement for neuronal cells in vitro cerebral ischemia/reperfusion and neuronal protection study [9, 10] . Panax notoginseng, one of the family of Acanthopanax gracilistylus, is a popular medicinal plant and displays a wide variety of pharmacological properties, such as sedation, antiinflammatory and analgesia activities [11] . Ginsenoside Rb 3 ( Figure 1 ) is a major component of protopanoxadiol triterpeProtective effects of ginsenoside Rb 3 on oxygen and glucose deprivation-induced ischemic injury in PC12 cells www.nature.com/aps Zhu JR et al Acta Pharmacologica Sinica npg noid saponin extracted from the leaves of Panax notoginseng. Ginsenoside Rb 3 was recently reported to exhibit the potential neuroprotective effects against ischemic damage in vivo, which decreased cerebral infarction and edema and improved neurological behavioral score in rats induced by transient cerebral ischemia [12, 13] . Notwithstanding the widespread study of ginsenoside Rb 3 , its related mechanism of neuroprotective effects against ischemic brain damage have remained unexplored. In order to further investigate the neuronal protective mechanisms of ginsenoside Rb 3 , the present study was designed to use NGF-differentiated PC12 cells as in vitro ischemia/reperfusion model , the initial phase of OGD mimics the obstruction of oxygen and glucose supply, the second phase of OGD-Rep reflects the reperfusion of oxygen and glucose supply to the injured brain.
Materials and methods

Drugs and reagents
Ginsenoside Rb 3 with a purity of 98% was obtained from Kunming Tongchi Pharmaceutical R&D Co, Ltd (Kunming, China). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), Propodium iodide (PI), Fura-2 acetoxymethyl ester (Fura-2AM) and α-tocopherol, rhodamine 123 (Rh123) were purchased from Sigma Chemical Co (MO, USA). Dulbecco's modified Eagle's medium (DMEM), glucose-free DMEM, fetal bovine serum (FBS) were obtained from Gibco (Carlsbad, CA USA). Annexin V-fluorescein isothioncyanate (FITC) apoptosis detection kit was obtained from Backman Coulter Inc (IM, USA). The chemical kits for the measurement of lactate dehydrogenase (LDH) were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Caspase-3, -8, -9 Activity Kits were acquired from Beyotime Institute of Biotechnology (Jiangsu Province, China). Antibody of cytochrome c, cleaved-caspase-3, Bcl-2, Bax, and β-actin were purchased from Cell Signaling Technology (Beverly, MA, USA). All other chemicals were of analytic grade and commercially available.
Cell culture NGF-differentiated PC12 cells, obtained from China Pharmaceutical University (Nanjing, China) were cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin at 37 °C in a humidified atmosphere of 5% CO 2 and 95% air. The medium was changed every two days, and the confluent cells were passaged by trypsinization weekly.
Drug treatment
Cells were plated at a density of 1.0×10 5 cells/mL 2 days before each experiment. To initiate OGD [14] , the cell culture medium was removed and replaced with the glucose-free DMEM, then the cells were incubated at 37 °C in an oxygen-free chamber (95% N 2 and 5% CO 2 ) for 4 h (OGD), and the change in oxygen levels of the culture medium were monitored during incubation in oxygen-free chamber. Following OGD, glucose was added to normal levels (final concentration: 4.5 mg/mL) and cells were incubated under normal growth conditions (95% air and 5% CO 2 ) for additional 24 h as OGD-reperfusion (OGDRep). Ginsenoside Rb 3 was freshly prepared as stock solution with dimethyl sulfoxide (DMSO) and diluted with phosphate buffer solution (PBS, pH 7.3), the final concentration of DMSO added to cells never exceeded 0.1%. Ginsenoside Rb 3 (final concentrations: 0.1, 1, 10 μmol/L) was added to the culture 24 h before OGD treatment and throughout the OGD reperfusion. The control culture was always maintained in normal DMEM and put in the incubator under normal conditions.
Assay for cell viability
The cell viability was evaluated by two methods: morphological observation with reversed-microscope and MTT reduction. Following the above cell treatment protocol, the morphology of the cells was observed and recorded as a photo under an Olympus Microscope (Tokyo, Japan). The medium was collected for MTT assay, which was quantified as previously described [15] . MTT stock solution in PBS was added to each well with a final concentration of 5 mg/mL, and the incubation continued for 4 h. Then, the medium with MTT was removed and the blue MTT-formazan was dissolved in DMSO. Optical density (OD) values were measured by spectrophotometry at 570 nm using an ELISA reader (ELx800uv, Bio Tek Instruments, USA). Cell viability was expressed as a percentage of OD value in the control cultures.
LDH release assay
Cytotoxicity was quantitatively assessed by measuring the activity of LDH released from the damaged cells into the culture medium [16] . At the end of treatments, PC12 cells were treated with 0.5% Triton X-100, and the media which contained detached cells were collected and centrifuged. The supernatant was used for the assay of LDH activity. The enzyme was 
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Flow cytometric apoptosis assay Apoptosis was assayed by annexin V-FITC and PI staining followed by analysis with fluorescene-activated cell sorting (FACS, BD FACScanto TM , San Jose, CA) equipped with the analysis software. The cultured PC12 cells were harvested after the treatment, and then the concentration was adjusted to 1.0×10 6 cells/mL with PBS. After that the PC12 cells were washed with 1×annexin V-FITC binding buffer before stained with annexin V-FITC and PI for 15 min at room temperature in the dark. Then the cells were analyzed by flow cytometry. Apoptotic and necrotic cells were quantitated by annexin V binding and PI uptake. The cell populations of annexin V-FITC + /PI -were calculated to represent apoptotic cells.
Determination of intracellular Ca
2+ concentration ([Ca 2+ ] i ) The intracellular Ca 2+ concentration was determined by the intensity of fluorescent Ca 2+ -sensitive dye, Fura 2-acetoxymethyl ester (Fura-2-AM) according to the method by Lenart [17] . The PC12 cells were loaded with Fura-2-AM (final concentration 5 mmol/L), 0.1% DMSO and 1% BSA for 30 min at room temperature in dark conditions, then in incubator for 30 min at 37 °C. Fluorescence measurement was carried out with an F-4500 fluorescence spectrophotometer (Hitachi, Japan). Fura-2-AM-loaded PC12 cells were exposed sequentially to an excitation wavelength of 340 nm and 380 nm (bandwidth 10 nm), and the emission signal was monitored at a wavelength of 510 nm (bandwidth 10 nm). Fluorescence ratios were converted into calcium concentrations by using the following equation: [18, 19] , where K d was 224 nmol/L, R(F 340 /F 380 )was fluorescence intensity. 
Measurement of mitochondrial membrane potential (MMP)
Diversities of mitochondrial membrane potential were assessed by using the fluorescent cationic dye Rh123 [20] , which accumulates in mitochondria as a direct function of the membrane potential and is released upon membrane depolarization. The PC12 cells (1. Western blot analysis PC12 cells were subjected to Western blot analysis for cleavedcaspase-3, Bcl-2, and Bax protein expression. Briefly, cells were lysed with lysis buffer [10 mmol/L Tris-HCl (pH 7.5), 0.5% CHAPS, 1 mmol/L EGTA, 5 mmol/L β-2-mercaptoethanol, 10% (v/v) glycerol, and 0.1 mmol/L phenylmethylsulfonyl fluoride] and incubated on ice for 30 min. After centrifugation at 10 000×g at 4 °C for 20 min, the supernatant extracts were quantified for protein using a BCA Protein Assay Kit. Cell proteins were separated by electrophoresis on 8% SDSpolyacrylamide gel (SDS-PAGE). After transferring to PVDF membranes, the membrane was blocked with nonfat milk and incubated overnight with primary antibody of cleaved -caspase-3, Bcl-2, and Bax at 4 °C. Antibody recognition was detected with the respective secondary antibody, anti-mouse or anti-rabbit IgG1 conjugated to horseradish peroxidase at room temperature for 2 h. Antibody-bound proteins were detected by Pierce's SupeSignal West Pico chemiluminescent substrate. β-actin served as an internal control.
Mitochondrial cytochrome c release assay
After the treatment, the cells were harvested by trypsinization followed by centrifugation. Then, cells were alysed with lysis buffer (75 mmol/L NaCl, 8 mmol/L Na 2 HPO 4 , 1 mmol/L NaH 2 PO 4 , 250 mmol/L sucrose, 1 mmol/L PMSF, 5 μg/mL, leupeptin, 12.5 μg/mL digitonin and 21 μg/mL aprotinin). After centrifugation at 10 000×g for 10 min, supernatant was collected and resolved in 15% denaturing SDS-PAGE minigel. Level of cytochrome c release from mitochondria was detected by probing with anti-cytochrome c antibody using Western blot analysis protocol as described above.
Measurement of caspase-3, -8, and -9 activities Caspases-3, -8, and -9 activities were measured using Caspase Activity Kit according to the manufacturer's instructions, using substrate peptides Ac-DEVD-pNA, Ac-IETD-pNA, and Ac-LEHD-pNA, respectively. Briefly, cells were lysed, then the supernatant was mixed with buffer containing the substrate peptides for caspase attached to p-nitroanilide (pNA). The release of pNA was qualified by determining the absorbance with an ELISA reader (Bio-Tek, USA) at 405 nm. The caspase activities were expressed as percentage compared to control.
Statistical analysis
All the data obtained in the experiments were represented as mean±standard deviation (SD). Statistical analysis was performed with the software package SPSS 10.0. Differences were determined using one-way analysis of variance (ANOVA). P values of less than 0.05 and 0.01 were regarded as statistically significant. Figure 2B ). However, the situation appeared much better in the groups pretreated with ginsenoside Rb 3 (0.1, 1, 10 μmol/L) ( Figure 2C , 2D, and 2E). It indicated some degree of protection against the OGD/OGD-Rep by ginsenoside Rb 3 .
As shown in Figure 3A , PC12 cell viability as determined by MTT reduction was also markedly decreased after the cell was exposed to OGD/OGD-Rep. But, when the cells were pretreated with ginsenoside Rb 3 (0. Flow cytometric analyses were carried out using Rh123, uptake of which by mitochondria is proportional to the MMP ( Figure 5B ). After exposure to OGD for 4 h followed by OGD-R for 24 h alone, the MMP of PC12 cells was significantly decreased to 32.48%±5.26% of that of control. However, the MMP decrease were dosedependently recovered significantly after being pre-incubated with 0.1, 1, 10 μmol/L ginsenoside Rb 3 24 h before OGD, up to 48.35%±4.98%, 68.65%±6.93%, 72.59%±9.11%, respectively.
Effects of ginsenoside Rb 3 on expressions of Bcl-2, Bax, cleavedcaspase 3 proteins and cytochrome c release The expression of proteins including cleaved-caspase 3, Bcl-2, and Bax may be involved in an intrinsic mitochondrial caspase pathway. In our case, an increase in the expression of the proapoptotic Bax, cleaved-caspase 3, and a decrease in the expression of the anti-apoptotic Bcl-2 after treatment of PC12 cells with OGD/OGD-Rep. Moreover, cytochrome c release from mitochondria into cytosol was also observed. Pretreatment with ginsenoside Rb 3 at the concentration of 1, 10 μmol/L antagonized all the above regulation induced by OGD/OGDRep. In addition, they significantly attenuated the decrease of the intracellular ratio of Bcl-2 to Bax ( Figure 6 ).
Ginsenoside Rb 3 inhibited the activities of caspase-3, -9, and -8 To investigate whether the blocking OGD/OGD-Rep-induced apoptosis by ginsenoside Rb 3 is dependent on caspase activation, we examined the activities of caspase-3, -9, and -8, which are initiating caspases in mitochondria-mediated apoptosis pathway. As shown in Figure 5C , after treatment of cells with OGD/OGD-Rep, the activities of caspase-3, -9, and -8 were enhanced by 3.4, 2.1, and 2.5-fold, as compared to control group respectively. However, pretreatment with ginsenoside Rb 3 (0.1, 1, 10 μmol/L) significantly attenuated these increase of caspase activities in a dose-dependent manner.
Discussion
It has been demonstrated that ischemic cell death signaling pathways was at least partly related to intrinsic mitochondriadependent and extrinsic receptor-mediated apoptosis pathways in the past few years [21, 22] . Although the mechanisms of how OGD-Rep worsen neural functions are not radically understood, cellular calcium dysregulation appears to be a common endpoint in the development of cerebral ischemia injury [23] . Energy failure in oxygen and glucose deprivationinduced ischemia can evoke the accumulation of intracellular Ca 2+ by enhancing the entry of Ca 2+ through NMDA receptors or release of Ca 2+ from the mitochondria through the Na + -Ca 2+ exchanger, and interfering with the ATP-dependent extrusion and sequestration of Ca 2+ [24] . Stained elevated Ca 2+ levels induced by OGD-Rep may impair mitochondrial function preceded by the opening of a permeability transition pore in the inner mitochondrial membrane, excessive release of glutamate, activate phospholipase, protease and endonucleases, eventually leading to neuronal apoptosis and death [25, 26] . Apoptosis is driven from the activation of a family of cysteine protease called caspases, which modulate the mitochondria-and death receptor-mediated pathways, respectively. In mitochondria mediated pathway, it is activation of the initiator caspase-9 that is responsible for subsequently activating caspase-3. Caspase-8 is a key initiating caspase involved in neuronal apoptosis through the death receptordependent. In addition, recent studies also suggested that caspase-8 was not always activated early in the death receptor-dependent pathway, but also in turn activated caspase-9 initiating the processing of caspase-3 in the mitochondria- Figure 6 . Effect of ginsenoside Rb 3 on the levels of cytochrome c release in the cytosolic fractions ( Figure 6A ), and the expression of cleaved caspase-3, Bcl-2, and Bax expression ( Figure 6B ) by Western blot analysis. PC12 cells were pre-incubated with 1 and 10 μmol/L ginsenoside Rb 3 for 24 h, respectively, and then exposed to OGD for 4 h followed by OGD-R for 24 h. At the end of treatment, cells were harvested for Western blotting with ß-actin as a protein loading control. Densitometric analyses of Western blot and the ratio of Bcl-2 to Bax are presented as the mean±SD for three independent experiments performed in triplicate, and the data are presented as the fold induction over control cells ( Figure 6C, 6D) [27] . In the process of ischemia, the Bcl-2 family of proteins, which consists of anti-apoptotic proteins of Bcl-2 and proapoptotic proteins of Bax, could mediate apoptosis by opening of mitochondrial permeability transition pore marked with the collapse of MMP, and down-regulation of the ratio of Bcl-2 to Bax has been reported to be correlated with the collapse of MMP [28, 29] . The opening of the mitochondrial permeability transition pore causes a release of pro-apoptotic proteins such as cytochrome c from mitochondria into cytoplasm [30] , and then, cytochrome c will bind to apoptotic protease-activating factor-1, and support the catalytic activation of caspase-9, which further cleaves and activates the effector caspase-3 resulting in the subsequent apoptosis event.
Recently, attention has been focused on finding the nature compounds with advantages of anti-apoptotic activity and low toxicity for neuroprotective agents [31, 32] . In this study, we used the oxygen and glucose deprivation-induced insult in PC12 cells to partially model the pathological process of cerebral ischemia. The present results showed that exposure of PC12 cells to OGD-Rep was followed by decreased cell viability, an increase in LDH leakage and elevation of the level of intracellular Ca 2+ , which was attenuated by ginsenoside Rb 3 in a concentration-dependent manner.
Pretreatment with ginsenoside Rb 3 significantly reduced apoptotic cells, the further results show that ginsenoside Rb 3 inhibited the increase in caspase-9, caspase-8, and caspase-3 activities which correlated with the increase in cytosolic cytochrome c levels induced by OGD. These suggested that protection of PC12 cells against OGD-Rep-induced apoptosis by ginsenoside Rb 3 involved mitochondria mediated pathways and caspase-8 may be the direct targets of ginsenoside Rb 3 on cell protection. Furthermore, ginsenoside Rb 3 upregulating the ratio of Bcl-2 to Bax may alter MMP, trigger the decrease of mitochondrial cytochrome c release into cytosol, and finally inhibited apoptosis via a mitochondria-mediated pathway.
In summary, ginsenoside Rb 3 protected PC12 cells against OGD-Rep induced ischemia/reperfusion injury. Such protective effects are mediated by its action on anti-apoptosis and suppression of the intracellular Ca 2+ elevation. Although a more precise mechanism of ginsenoside Rb3 on these molecular targets and whether a death receptor-mediated pathway involved in the protection should be investigated in further studies, the present findings provided a preliminary pharmacological basis for the therapeutic efficacy of ginsenoside Rb 3 for cerebral ischemia.
